Production (Stage)
Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.032.50%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 16.27% | 8.95% | -5.81% |
| Total Depreciation and Amortization | -- | -- | -15.79% | 0.00% | 14.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 83.08% | 32.02% | -34.59% |
| Change in Net Operating Assets | -- | -- | 57.05% | -116.03% | -41.21% |
| Cash from Operations | -- | -- | 28.82% | -4.17% | -26.00% |
| Capital Expenditure | -- | -- | -- | -100.00% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -56.80% | -129.56% | 54.35% |
| Cash from Investing | -- | -- | -56.80% | -129.57% | 54.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 71,000.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 71,000.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 111.40% | -243.33% | 160.84% |